我武生物
(300357)
| 流通市值：94.25亿 | | | 总市值：101.94亿 |
| 流通股本：4.84亿 | | | 总股本：5.24亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,086,477,440.79 | 1,223,125,711.39 | 1,195,259,993.17 | 1,171,377,407.31 |
| 应收票据及应收账款 | 247,441,098.85 | 198,902,387.83 | 188,033,525.9 | 161,583,153.69 |
| 其中：应收票据 | 17,596,301.06 | 13,711,895.36 | 11,776,703.84 | 18,620,344.02 |
| 应收账款 | 229,844,797.79 | 185,190,492.47 | 176,256,822.06 | 142,962,809.67 |
| 应收款项融资 | 68,712,659.39 | 42,790,657.93 | 39,165,729.23 | 41,337,947.58 |
| 预付款项 | 5,271,617.09 | 4,959,097 | 5,343,686.62 | 5,819,065.18 |
| 其他应收款合计 | 8,010,838.23 | 7,956,522.12 | 7,200,985.39 | 6,196,880.15 |
| 存货 | 52,513,651.44 | 61,756,217.31 | 60,086,525.6 | 59,037,504.11 |
| 其他流动资产 | 15,330,282.5 | 13,818,293.73 | 12,776,532.04 | 7,155,301.43 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,648,880,999.51 | 1,648,225,882.54 | 1,595,653,977.74 | 1,569,894,078.45 |
| 非流动资产: | | | | |
| 长期股权投资 | 72,769,757.9 | 73,107,973.42 | 73,723,183.13 | 74,213,191.37 |
| 其他权益工具投资 | 5,428,577.14 | 5,428,577.14 | 5,403,206.52 | - |
| 固定资产 | 448,464,228.4 | 450,290,754.24 | 449,379,790.06 | 448,616,840.96 |
| 在建工程 | 311,238,189.23 | 275,020,564.34 | 261,765,009.8 | 227,855,260.19 |
| 使用权资产 | 13,845,559.24 | 24,995,487.53 | 26,805,466.47 | 28,368,795.1 |
| 无形资产 | 152,248,173.14 | 154,873,421.8 | 158,171,747.36 | 161,382,462.31 |
| 开发支出 | 30,664,553.39 | 29,011,293.18 | 28,103,170.57 | 27,037,442.44 |
| 长期待摊费用 | 6,609,896.99 | 6,916,442.59 | 6,894,846.19 | 7,340,894.48 |
| 递延所得税资产 | 6,501,058.95 | 5,947,504.24 | 5,233,202.47 | 5,034,520.57 |
| 其他非流动资产 | 4,394,465.72 | 7,789,820 | 13,006,770 | 12,423,230 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,052,164,460.1 | 1,033,381,838.48 | 1,028,486,392.57 | 992,272,637.42 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,701,045,459.61 | 2,681,607,721.02 | 2,624,140,370.31 | 2,562,166,715.87 |
| 流动负债: | | | | |
| 短期借款 | 37,215,612.61 | 44,365,782 | 49,173,249.53 | 34,391,759.19 |
| 应付票据及应付账款 | 8,165,059.01 | 7,552,205.38 | 7,489,563.16 | 7,991,954.63 |
| 应付账款 | 8,165,059.01 | 7,552,205.38 | 7,489,563.16 | 7,991,954.63 |
| 合同负债 | 1,383,934.89 | 1,422,535.64 | 1,497,008.29 | 384,279.44 |
| 应付职工薪酬 | 24,219,485.75 | 19,790,316.42 | 19,752,004.99 | 29,035,505.84 |
| 应交税费 | 30,075,811.66 | 17,052,688.28 | 19,033,368.89 | 14,502,342.06 |
| 其他应付款合计 | 57,192,942.56 | 151,621,910.07 | 57,764,951.11 | 83,939,171.54 |
| 应付股利 | - | 96,863,038.72 | - | - |
| 一年内到期的非流动负债 | 5,141,140.15 | 6,829,731.61 | 7,206,732.62 | 6,795,183.91 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 163,393,986.63 | 248,635,169.4 | 161,916,878.59 | 177,040,196.61 |
| 非流动负债: | | | | |
| 租赁负债 | 8,365,071.56 | 17,748,217.73 | 19,528,597.03 | 21,256,115.9 |
| 递延收益 | 33,972,259.95 | 34,410,503.01 | 30,493,326.07 | 30,931,569.13 |
| 递延所得税负债 | 177,802.81 | 176,735.38 | 202,253.94 | 203,236.78 |
| 其他非流动负债 | 25,796,286.43 | 25,796,286.43 | 29,029,182.86 | 29,029,182.86 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 68,311,420.75 | 78,131,742.55 | 79,253,359.9 | 81,420,104.67 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 231,705,407.38 | 326,766,911.95 | 241,170,238.49 | 258,460,301.28 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 523,584,000 | 523,584,000 | 523,584,000 | 523,584,000 |
| 资本公积 | 128,194,388.22 | 128,194,388.22 | 128,194,388.22 | 128,194,388.22 |
| 其他综合收益 | 29,429.14 | 5,406,022.28 | 5,378,683.48 | 30,850.8 |
| 盈余公积 | 270,715,165.14 | 270,715,165.14 | 270,715,165.14 | 270,715,165.14 |
| 未分配利润 | 1,437,966,005.06 | 1,314,943,005.56 | 1,339,782,370.99 | 1,262,575,050.26 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,360,488,987.56 | 2,242,842,581.2 | 2,267,654,607.83 | 2,185,099,454.42 |
| 少数股东权益 | 108,851,064.67 | 111,998,227.87 | 115,315,523.99 | 118,606,960.17 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,469,340,052.23 | 2,354,840,809.07 | 2,382,970,131.82 | 2,303,706,414.59 |
| 负债和股东权益合计 | 2,701,045,459.61 | 2,681,607,721.02 | 2,624,140,370.31 | 2,562,166,715.87 |
| 公告日期 | 2024-10-24 | 2024-08-23 | 2024-04-19 | 2024-04-19 |
| 审计意见(境内) | | | | 标准无保留意见 |